Search Browse Earnings

Kronos Bio, Inc.

Pharmaceutical Preparations·SAN MATEO, CA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Kronos Bio, Inc. — SlamSEC

Revenue

$6.3M

FY 2024

Adj. EBITDA

-$119.9M

-1907.5% margin

FY 2024

Net Income

-$112.7M

-1791.9% margin

FY 2024

EPS (Diluted)

-$1.95

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$64.3M

FY 2024

Total Debt

—

Net Cash

$64.3M

FY 2024

Enterprise Value

—

Debt / EBITDA

0.5x

FY 2024

EV / EBITDA

—

Employees

—